MENU
JUN 20, 2019 7:30 AM PDT

Keynote Presentation: The Impact of Patient-to-Patient Variability on Combination Cancer Therapy and Precision Oncology

C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Systems Biologist, Laboratory of Systems Pharmacology, Harvard Medical School
    Biography
      Adam Palmer is a systems biologist working on the analysis and design of combination cancer therapies. Adam applies experiments, theory, and analysis of data from clinical trials of cancer therapies, with a particular interest in the origins and therapeutic consequences of cell-to-cell and patient-to-patient heterogeneity in cancers. Adam is presently a postdoctoral fellow with Peter Sorger in the Laboratory of Systems Pharmacology at Harvard Medical School. Previously, Adam completed his Ph.D in Systems Biology at Harvard University with Roy Kishony, researching the relationships between mechanisms of drug action and the evolution of antibiotic resistance.

    Abstract

    Most cancer therapies have highly variable activity from one patient to another, with only a fraction of patients’ cancers responding to a given treatment. In many types of cancer, combination therapies can improve the probability of response. Since 1961 it was known that combinations of individually active therapies can be expected to improve response rate to some degree simply by increasing each patient’s chance of receiving at least one personally effective therapy. Here I describe recent analyses of contemporary combination therapies showing that this phenomenon of patient-to-patient variability in single-drug activity accounts for the clinical activity of many approved combination cancer therapies. These results highlight widespread opportunities to make more precise use of cancer therapies both individually and in combinations.

    Learning Objectives: 

    1. How patient-to-patient variability in response to individual cancer therapies affects responses to combinations of cancer therapies, and the implications for precision medicine in oncology.
    2. How to calculate the 'independent effect' Progression Free Survival distribution for a combination of cancer therapies, which can be used to analyze clinical trial results, and to predict the activity of combinations of independently acting drugs.


    Show Resources
    You May Also Like
    MAY 11, 2021 10:00 AM PDT
    C.E. CREDITS
    MAY 11, 2021 10:00 AM PDT
    Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    MAR 16, 2021 10:00 AM PDT
    C.E. CREDITS
    MAR 16, 2021 10:00 AM PDT
    Date: March 16, 2021 Time: 10:00am (PST) Scientific progress and breakthroughs today are often too expensive for most institutions to acquire. Each year, the National Institutes of Health (N...
    APR 01, 2021 8:00 AM PDT
    C.E. CREDITS
    APR 01, 2021 8:00 AM PDT
    Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
    JUN 20, 2019 7:30 AM PDT

    Keynote Presentation: The Impact of Patient-to-Patient Variability on Combination Cancer Therapy and Precision Oncology

    C.E. Credits: P.A.C.E. CE Florida CE

    Specialty

    Clinical Diagnostics

    Gene Expression

    Cancer Diagnostics

    Biomarkers

    Cancer Research

    Dna

    Neuroscience

    Cancer

    Infectious Disease

    Genomics

    Animal Research

    Immunity

    Cell Biology

    Gene Sequencing

    Research

    Geography

    North America43%

    Asia43%

    Europe14%

    Registration Source

    Website Visitors100%

    Job Title

    Educator/Faculty33%

    Student17%

    Pathologist17%

    Medical Laboratory Technician17%

    Lab Management17%

    Organization

    Academic Institution43%

    Manufacturer - Other14%

    Medical Device Company14%

    Clinical Laboratory14%

    Hospital14%


    Show Resources
    Loading Comments...
    Show Resources